A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy

BACKGROUND AND PURPOSE: Patients with hepatocellular carcinoma (HCC) commonly have underlying liver dysfunction with variable tolerance to liver stereotactic body radiation therapy (SBRT). We hypothesized that insertion of a 1-month mid-treatment break would allow us to adapt treatment to the indivi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Radiother Oncol
Main Authors: Jackson, W.C., Suresh, K., Maurino, C., Feng, M., Cuneo, K.C., Ten Haken, R.K., Lawrence, T.S., Schipper, M.J., Owen, D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988412/
https://ncbi.nlm.nih.gov/pubmed/31431377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2019.07.027
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados